Medicare Lab Test Pricing Forum Set for July 10
The Centers for Medicare and Medicaid Services (CMS) will hold a public meeting July 10 at its Baltimore headquarters to hear recommendations on setting Medicare payment rates for new or substantially revised clinical laboratory codes for the Part B lab fee schedule in 2014. All presenters for the public meeting must register and submit their presentations electronically to Glenn McGuirk by June 28: Glenn.McGuirk@cms.hhs.gov. The agency announced the meeting in the May 24 Federal Register. Comments on the new or revised codes are due by June 28. CMS will determine pricing of the codes either through crosswalking (mapping to an existing code) or gap-filling (pricing determined by Medicare contractors based on charges, resources, and payment amount determined by other payers). The agency plans to publish proposed determinations for new and reconsidered codes for 2014 by early September. Final fee decisions are expected in November. For the 2014 clinical laboratory fee schedule, there are 16 new Current Procedural Terminology codes and 11 reconsideration requests. (Note: numbering of new codes will be finalized later.) NEW AND RECONSIDERED CODES FOR THE 2014 MEDICARE LAB FEE SCHEDULE* NEW TEST CODES THERAPEUTIC DRUG ASSAYS 801XX1 Caffeine 801XX2 Clozapine 801XX3 Everolimus 801XX4 Gabapentin 801XX5 Lamotrigine 801XX6 […]
NEW AND RECONSIDERED CODES FOR THE 2014 MEDICARE LAB FEE SCHEDULE* | |
NEW TEST CODES | |
THERAPEUTIC DRUG ASSAYS | |
801XX1 | Caffeine |
801XX2 | Clozapine |
801XX3 | Everolimus |
801XX4 | Gabapentin |
801XX5 | Lamotrigine |
801XX6 | Levetiracetam |
801XX7 | Mycophenolate (mycophenolic acid) |
801XX8 | Oxcabazepine |
801XX9 | Tiagabine |
802XX | Zonisamide |
TIER 1 MOLECULAR PATHOLOGY PROCEDURES | |
81161 | DMD (dystrophin) (eg, Duchenne/Becker muscular dystrophy) deletion analysis, and duplication analysis, if performed |
812XX | MGMT (O6-methylguanine DNA methyltransferase) (eg, Brain Cancer) allele specific identification of dense promoter methylation, analysis of the MGMT gene, prognostic/predictive for response for treatment which include alkylating agents such as temozolamide therapy in tumor tissue |
MULTIANALYTE ASSAYS WITH ALGORITHMIC ANALYSES | |
815XX1 | Oncology (tissue of origin), microarray gene expression profiling of > 2000 genes, utilizing formalin-fixed paraffin embedded tissue, algorithm reported as tissue similarity scores |
815XX2 | Fetal aneuploidy (trisomy 21, 18, and 13) DNA sequence analysis of selected regions using maternal plasma, algorithm reported as a risk score for each trisomy |
81508 | Fetal congenital abnormalities, biochemical assays of two proteins (PAPP-A, hCG [any form]), utilizing maternal serum, algorithm reported as a risk score |
MICROBIOLOGY | |
876XX | Infectious agent detection by nucleic acid (DNA or RNA); Trichomonas vaginalis, amplified probe technique |
RECONSIDERATION REQUESTS | |
0001M | Infectious disease, HCV, six biochemical assays (ALT, A2-macroglobulin, apolipoprotein A-1, total bilirubin, GGT, and haptoglobin) utilizing serum, prognostic algorithm reported as scores for fibrosis and necroinflammatory activity in liver |
0002M | Liver disease, ten biochemical assays (ALT, A2-macroglobulin, apolipoprotein A-1, total bilirubin, GGT, haptoglobin, AST, glucose, total cholesterol and triglycerides) utilizing serum, prognostic algorithm reported as quantitative scores for fibrosis, steatosis and alcoholic steatohepatitis (ASH) |
0003M | Liver disease, ten biochemical assays (ALT, A2-macroglobulin, apolipoprotein A-1, total bilirubin, GGT, haptoglobin, AST, glucose, total cholesterol and triglycerides) utilizing serum, prognostic algorithm reported as quantitative scores for fibrosis, steatosis and nonalcoholic steatohepatitis (NASH) |
81500 | Oncology (ovarian), biochemical assays of two proteins (CA-125 and HE4), utilizing serum, with menopausal status, algorithm reported as a risk score |
81503 | Oncology (ovarian), biochemical assays of five proteins (CA-125, apoliproprotein A1, beta-2 microglobulin, transferrin, and pre-albumin), utilizing serum, algorithm reported as a risk score |
81506 | Endocrinology (type 2 diabetes), biochemical assays of seven analytes (glucose, HbAlc, insulin, hs-CRP, adoponectin, ferritin, interleukin 2-receptor alpha), utilizing serum or plasma, algorithm reporting a risk score |
81509 | Fetal congenital abnormalities, biochemical assays of three proteins (PAPP-A, hCG [any form], DIA), utilizing maternal serum, algorithm reported as a risk score |
81510 | Fetal congenital abnormalities, biochemical assays of three analytes (AFP, uE3, hCG [any form]), utilizing maternal serum, algorithm reported as a risk score |
81511 | Fetal congenital abnormalities, biochemical assays of four analytes (AFP, uE3, hCG [any form], DIA) utilizing maternal serum, algorithm reported as a risk score (may include additional results from previous biochemical testing) |
81512 | Fetal congenital abnormalities, biochemical assays of five analytes (AFP, uE3, total hCG, hyperglycosylated hCG, DIA) utilizing maternal serum, algorithm reported as a risk score |
82777 | Galectin-3 |
Source: www.cms.gov/ClinicalLabFeeSched/. Click on “Laboratory Public Meetings” to access the download. *CMS: Any changes to the list will be updated as they occur. CPT codes copyright American Medical Association. |
Subscribe to view Essential
Start a Free Trial for immediate access to this article